All In Biotech

Drug Trial Radar · NCT02786537

Study of Oral Treatments for Hepatitis C

THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders

Last checked: Nov 19, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,275

Actual

Start

Jun 2016

Primary completion

Jun 13, 2019

Study completion Sep 2, 2020

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Patient-Centered Outcomes Research Institute; Merck Sharp & Dohme LLC; AbbVie
First posted
Jun 1, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 of this study compared the effectiveness of 3 approved DAA (direct-acting antiviral) HCV treatment regimens to learn whether they worked equally well under real-world conditions. Phase 2 of this study began early 2017 with removal of 1 DAA regimen, limiting randomization to just 2 FDA approved DAA regimens. Patients receiving HCV therapy in community and academic clinics were offered the opportunity to consent to be randomly assigned to one of three (phase 1) or one of two (phase 2) regimens and observed for outcomes. Once randomized, all medical care, laboratory testing, and any disease or side effect management were assumed by usual care conditions, and patient-reported outcomes were collected outside clinic in keeping with pragmatic design principles.

Conditions

  • Chronic Hepatitis C

Interventions

  • SOF/LDV (sofosbuvir/ledipasvir)Drug

    Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)

  • PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)Drug

    Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) (2 tablets taken orally) and Dasabuvir (250 mg tablet) (1 tablet twice daily) with food for 12 to 24 weeks (treatment duration as per HCV provider)

  • EBR/GZR (elbasvir/grazoprevir)Drug

    Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks

  • RibavirinDrug

    200 mg pills (1-3 pills, 1-2 times per day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained Virologic Response (SVR12) mITT With Imputation-Phase 1 and 2 EBR/GZR, SOF/LDVTime frame: 12 weeks post-treatment
  2. Phase 1/2 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)Time frame: 12-24 weeks post HCV treatment
  3. Phase 1-Sustained Virologic Response (SVR12) mITT With ImputationTime frame: 12 weeks post-treatment
  4. Phase 1 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)Time frame: 12 -24 weeks post-treatment
  5. Mean Change in Headache-PRO Scores -Phase 1Time frame: Baseline to On-Treatment
  6. Mean Change in Headache-EBR/GZR and SOF/LDVTime frame: Baseline to On-Treatment
  7. Median Change in Headache -Phase 1Time frame: 12 weeks (Baseline and Average On-treatment Score)
  8. Median Change in Headache-Phase 2Time frame: Baseline -on Treatment (12-16 weeks)
  9. Mean Change in Nausea/Vomiting PRO Score -Phase 1Time frame: Baseline to On-Treatment
  10. Mean Change in Nausea/Vomiting PROMIS Score -EBR/GZR vs. LDV/SOFTime frame: Baseline and Average On-Treatment Score
  11. Median Change in Nausea PRO Score -Phase 1Time frame: Baseline to end of treatment
  12. Median Change in Nausea PROMIS Score-EBR/GZR SOF/LDVTime frame: Baseline- On Treatment (up to 16 weeks)
  13. Mean Change in Fatigue PRO Score -Phase 1Time frame: Baseline to On-treatment
  14. Mean Change in Fatigue PRO -EBR/GZR vs SOF/LDVTime frame: Baseline and Average On-Treatment Score
  15. Median Change in Fatigue -Phase 1Time frame: Baseline to End of Treatment
  16. Median Change in Fatigue-Phase 2Time frame: Baseline-On Treatment (up to 16 weeks)
  17. Mean Change in HCV- PRO- Phase 1Time frame: Baseline to End of Treatment
  18. Median Change in HCV-PRO (Overall Well Being) -Phase 1Time frame: Baseline to End of Treatment
  19. Mean Change in HCV-PRO (Functional Well-being) EBR/GZR vs. SOF/LDV Score-Phase 2Time frame: End of Treatment - Baseline
  20. 16 Wk EBR/GZR With RBV Efficacy on Patients With HCV RASsTime frame: 12 weeks post treatment

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Liver Wellness Center

    Little Rock, Arkansas

  • Stanford University

    Palo Alto, California

  • UCSD Medical Center

    San Diego, California

  • UCSF/Zuckerberg San Francisco General Hospital and Trauma Center

    San Francisco, California

  • Univ of California, San Francisco

    San Francisco, California

  • Yale University Digestive Diseases

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • Howard University

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • University of Florida, Jacksonville

    Jacksonville, Florida

  • University of Miami/Schiff Center for Liver Diseases

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Internal Medicine Associates of Wellstar Atlanta Medical Center

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • Indiana University Medical Center

    Indianapolis, Indiana

  • John Hopkins University

    Lutherville, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • GI Associates & Endoscopy Center

    Flowood, Mississippi

  • Saint Louis University

    St Louis, Missouri

  • University of Nebraska Medical Ctr

    Omaha, Nebraska

  • Southwest CARE Center

    Santa Fe, New Mexico

  • Mt. Sinai Beth Israel

    New York, New York

  • New York Langone Medical Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Mountain View Medical Center

    Valatie, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Research Specialist of Texas

    Houston, Texas

  • Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia)

    Richmond, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • Virginia Mason Medical Center

    Seattle, Washington

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.